NCT06102369

Brief Summary

Investigators conducted an observational diagnostic study. The primary objective of the study is to develop a scoring system for detecting pre-lung cancer abnormalities using narrow-band imaging (NBI) bronchoscopy. From the collected data, investigators will perform a multivariate analysis based on the odds ratio (OR) using IBM SPSS software. The result of the data analysis will be transformed into a scoring system aimed to facilitate the early diagnosis of lung cancer, specifically at the pre-cancer stage. This scoring system will also help clinicians detect pre-cancerous abnormalities early and improve patient recovery prospects. Several research questions to be addressed are as follows:

  1. 1.What are the NBI image criteria for detecting pre-cancerous lesions in lung tumor patients?
  2. 2.What is the diagnostic profile of NBI bronchoscopy in detecting pre-cancerous lesions in lung tumor patients?
  3. 3.Can adding the NBI bronchoscopy procedure to the standard bronchoscopy procedure enhance the diagnostic accuracy in detecting pre-cancerous lesions in lung tumor patients?

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2023

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 27, 2023

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 22, 2023

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 26, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2024

Completed
Last Updated

March 6, 2024

Status Verified

March 1, 2024

Enrollment Period

1 year

First QC Date

October 22, 2023

Last Update Submit

March 4, 2024

Conditions

Keywords

bronchoscopynarrow-band imaging (NBI)lung cancerbronchial squamous dysplasia

Outcome Measures

Primary Outcomes (1)

  • To determine the sensitivity, specificity, positive predictive value, and negative predictive value of the bronchoscopic narrow-band imaging (NBI) in detecting bronchial squamous dysplasia

    To address this outome, researchers will utilize parameters derived form NBI bronchoscopy images, consist of normal vascularity, increased vascular frequency, dotted, spiral, tortuous and abrupt-ending blood vessels (on a nominal scale). These parameters will be employed in conjunction with histopathological images (dysplasia or non dysplasia) for comparative analysis

    Based on the research timeline, all statistical analysis and data processing will be conducted from January to February 2024

Secondary Outcomes (2)

  • To determine the proportion of bronchial squamous dysplasia in lung cancer patients

    Based on the research timeline, all statistical analysis and data processing will be conducted from January to February 2024

  • To establish the correlation between the NBI bronchoscopy findings and bronchial squamous dysplasia in lung cancer patients

    Based on the research timeline, all statistical analysis and data processing will be conducted from January to February 2024

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Population: The target population consists of all lung tumor patients. The accessible population consisted of lung tumor patients who underwent bronchoscopy procedures at Persahabatan Hospital from March to December 2023. 2. The study participants: The study participants comprised individuals from the accessible population who met the research subject acceptance criteria and provided informed consent. The consecutive sampling method was employed. 3. The study participants size calculation: The study participants size was calculated using the diagnostic research sample size formula. The minimum study participants size required was 110 subjects.

You may qualify if:

  • Patients aged \>18 years undergoing bronchoscopy for diagnostic evaluation of lung tumors.
  • Recent radiological examinations, including both chest X-rays and chest CT scans, within the last month, revealed central lesions.

You may not qualify if:

  • Refusal to provide informed consent
  • Contraindications to bronchoscopy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine

Jakarta Pusat, DKI Jakarta, 10430, Indonesia

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

formalin-fixed paraffin-embedded (FFPE) tissue

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 22, 2023

First Posted

October 26, 2023

Study Start

March 27, 2023

Primary Completion

March 31, 2024

Study Completion

October 30, 2024

Last Updated

March 6, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Researchers might be engaging in consultations with ethics boards, legal experts, and stakeholders to develop a robust and ethical sharing plan that adheres to the highest standards of privacy and security.

Locations